RESUMEN
Preemptive analgesia is an important part of surgical management, but some NSAIDs can adversely affect platelet function or renal or hepatic status. Tepoxalin is approved in the United States for control of pain and inflammation associated with arthritis and in Europe for relief of pain caused by musculoskeletal disorders. In this study, no significant effects on indices of hemostasis or renal or hepatic function were detected when a single preoperative oral dose of tepoxalin was administered to young healthy dogs undergoing anesthesia and surgery.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Hemostasis/efectos de los fármacos , Riñón/efectos de los fármacos , Hígado/efectos de los fármacos , Medicación Preanestésica/veterinaria , Pirazoles/administración & dosificación , Analgesia/métodos , Analgesia/veterinaria , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/farmacología , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/prevención & control , Perros , Femenino , Hemostasis Quirúrgica , Riñón/fisiología , Hígado/fisiología , Masculino , Dolor/tratamiento farmacológico , Dolor/prevención & control , Dolor/veterinaria , Pirazoles/efectos adversos , Pirazoles/farmacología , Distribución Aleatoria , Resultado del TratamientoRESUMEN
Plasma and skin concentrations of orbifloxacin (Orbax tablets, Schering-Plough Animal Health) were assessed in 14 clinically normal dogs and 14 dogs with pyoderma following oral administration of the drug at 7.5 mg/kg once daily for 5 to 7 days. Skin biopsies and whole blood samples were obtained before dosing and at the time of the expected maximum concentration in skin (3 hours after dosing) on the first and on the fifth to seventh day of dosing. Skin biopsies and plasma were analyzed for orbifloxacin concentrations by high-performance liquid chromatography. Dogs with pyoderma had significantly higher mean skin concentrations of orbifloxacin within 3 hours of administration (Day 0: 7.80 +/- 3.40 mcg/g, Days 4 to 6: 9.47 +/- 6.23 mcg/g) than did dogs with normal skin (Day 0: 3.85 +/- 1.08 mcg/g, Days 4 to 6: 5.43 +/- 1.02 mcg/g). After dosing on Day 0 and after five to seven daily treatments, dogs with pyoderma had significantly higher mean orbifloxacin skin:plasma ratios (1.40 and 1.44, respectively) than did clinically normal dogs (0.81 and 0.96, respectively). The accumulation of orbifloxacin in diseased skin may contribute to the efficacy of this compound for the treatment of bacterial skin infections.